Epilepsy in Angelman’s Syndrome

被引：0

作者：

Bobylova M.Y. ^{[1
]}

Mukhin K.Y. ^{[1
]}

Kuzmich G.V. ^{[1
]}

Glukhova L.Y. ^{[1
]}

Pylayeva O.A. ^{[1
]}

机构：

[1] St. Luke Institute of Child Neurology and Epilepsy, Troitsk, Moscow

来源：

Neuroscience and Behavioral Physiology | 2023年 / 53卷 / 3期

关键词：

Angelman syndrome; benign juvenile epileptiform patterns; EEG δ-θ-occipitoparieto-temporal slowing pattern (δ-θ-OPT); epilepsy; notched; δ; activity; UBE3A gene; video-EEG monitoring;

D O I：

10.1007/s11055-023-01425-5

中图分类号：

学科分类号：

摘要：

Objectives. To study the neurological status, clinical/EEG patterns, neuroimaging, and the course of epilepsy in children with genetically confirmed Angelman syndrome. Materials and methods. Data from 47 patients (26 boys and 21 girls aged 2–20 (mean 8.5) years) with genetically verified diagnoses of Angelman’s syndrome were analyzed. Diagnoses were established by DNA methylation analysis in 32 patients and sequencing in 15 (among which there were 12 cases of deletion and three with nucleotide substitutions). Results. Epilepsy was detected in 45 of 47 patients. Seizure debut was at age up to 5 years inclusive. Treatment was with a variety of antiepileptic drugs. Long-term epilepsy follow-up in 40 out of 47 patients showed that drug remission was achieved in 36 of these 40 patients. Relapse after several years of remission occurred in 24 of 36 patients, with rapid recovery in 23 patients. Disease severity was influenced by the type of mutation and the extent of deletions, as well as persistent epileptic seizures. The most effective antiepileptic drugs in study patients were valproic acid, levetiracetam, and ethosuximide as monotherapy, as well as valproic acid in combination with levetiracetam or ethosuximide and, less often, levetiracetam combined with ethosuximide in dual therapy. Conclusions. Early genetic diagnosis of Angelman’s syndrome facilitates the selection of antiepileptic therapy. © 2023, Springer Nature Switzerland AG.

引用

页码：302 / 307

页数：5

共 24 条

[1]

Online Mendelian Inheritance in Man (OMIM) Database

[2]

Dagli A.I., Mueller J., Williams C.A., Angelman syndrome,”, University of Washington, Seattle, (1993)

[3]

Williams C.A., Beaudet A.L., Clayton-Smith J., Et al., Angelman syndrome 2005: updated consensus for diagnostic criteria, Am. J. Med. Genet. A, 140, 5, pp. 413-418, (2006)

[4]

Williams C., Driscoll D., Dagli A., Clinical and genetic aspects of Angelman syndrome, Genet. Med., 12, pp. 385-395, (2010)

[5]

Williams C.A., Angelman syndrome,”, In: Management of Genetic Syndromes, pp. 69-80, (2010)

[6]

Fumara A., Pittala A., Cocuzza M., Et al., Epilepsy in patients with Angelman syndrome, Ital. J. Pediatr., 36, (2010)

[7]

Gobbi G., Genton P., Pini A.

[8]

Valente K.D., Fridman C., Varela M.C., Et al., Angelman syndrome: uniparental paternal disomy 15 determines mild epilepsy, but has no influence on EEG patterns, Epilepsy Res., 67, 3, pp. 163-168, (2005)

[9]

Valente K.D., Koiffmann C.P., Fridman C., Et al., Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11–q13, Arch. Neurol., 63, pp. 122-128, (2006)

[10]

Thibert R.L., Conant K.D., Braun E.K., Et al., Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options, Epilepsia, 50, 11, pp. 2369-2376, (2009)

← 1 2 3 →